Brii Biosciences
Brii Biosciences develops therapies for diseases with significant unmet medical needs, focusing on infectious and central nervous system diseases, and operates in key biotech hubs globally.
Services
Brii Biosciences focuses on developing therapies for diseases with significant unmet medical needs and large public health burdens. The company specializes in addressing infectious diseases and central nervous system disorders. Their approach involves leveraging patient insights and experiences to guide the development of potential treatment options. This patient-centric focus ensures that the therapies they develop are both effective and aligned with the actual needs of those suffering from these conditions.
Global Operations
Brii Biosciences operates in key biotechnology hubs including Raleigh-Durham, the San Francisco Bay Area, Beijing, and Shanghai. These strategic locations allow the company to integrate diverse perspectives in research, development, and market access, as well as foster collaborations with leading institutions across the biotech field. This global presence supports their mission to address pressing healthcare challenges worldwide.
Stock Market Information
Brii Biosciences is publicly traded on the Hong Kong Stock Exchange under the stock code 2137.HK. The company has been listed since July 13, 2021. Being included in the Hang Seng Composite Index and Hong Kong Stock Connect highlights the company’s prominence and investor interest within the market.
Financial Milestones
Brii Biosciences successfully closed a US$155 million Series C financing round, underscoring strong investor confidence and financial stability. This funding is instrumental in advancing their research and development initiatives, particularly in their efforts to deliver innovative therapies for critical healthcare needs.
Significant Projects
Brii Biosciences has made significant progress in developing treatments for COVID-19. Their monoclonal antibodies, BRII-196 and BRII-198, have advanced to Phase 3 in the NIH ACTIV-2 trial for ambulatory COVID-19 patients. Additionally, the amubarvimab/romlusevimab combination received approval from the National Medical Products Administration (NMPA) as the first COVID-19 neutralizing antibody combination therapy in China. These advancements reflect the company's commitment to addressing urgent healthcare challenges with innovative solutions.